ArticleJournal of inflammation research2025
Bone Marrow Mesenchymal Stem Cells Can Prevent Pancreatic Fibrosis in Mice with Chronic Pancreatitis by Inhibiting the Activation of Pancreatic Stellate Cells.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic pancreatitis (CP) is a progressive fibroinflammatory disorder primarily driven by a complex interplay of environmental and genetic risk factors. Fibrosis, mediated by activated pancreatic stellate cells (PSCs), represents a key pathological feature of CP. Bone marrow mesenchymal stem cells (BMSCs) are known for their anti-fibrotic and anti-inflammatory properties; however, their role in pancreatic fibrosis remains inadequately understood. Aim of the Study: This study aims to investigate the effects of BMSCs on CP and elucidate the underlying mechanisms. Methods: To evaluate the effects of BMSCs on pancreatic tissue alterations in CP, a mouse CP model was established using Ceruletide, followed by tail vein injection of BMSCs. Histological assessments of pancreatic injury were performed using hematoxylin and eosin (H&E) staining and Masson's trichrome staining. The role of BMSCs in PSC activation and function was investigated through co-culture experiments with PSCs. Furthermore, to elucidate the underlying mechanisms by which BMSCs influence PSCs, transcriptomic analysis of PSCs was performed to identify key molecules and signaling pathways. Results: In vivo, BMSCs mitigated pathological changes and collagen deposition while suppressing PSC activation in CP mice. In vitro, BMSCs inhibited PSC activation and function, as evidenced by reduced collagen secretion, decreased proliferation, and increased apoptosis. RNA sequencing identified the aryl hydrocarbon receptor (AhR) and peroxisome proliferator-activated receptor gamma (PPARγ) as potential key mediators. Notably, AhR antagonism reversed the inhibitory effects of BMSCs on PSCs and attenuated the BMSC-induced upregulation of PPARγ in PSCs. Conclusion: Transplantation of BMSCs suppresses PSCs activation and attenuates the pancreatic fibrosis in CP. This process may be mediated by the activation of AhR and PPARγ in PSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.